Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Madrigal Pharmaceuticals (MDGL) Change in Intangibles (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Intangibles for 2 consecutive years, with $3.0 million as the latest value for Q3 2025.

Quarterly Change in Intangibles changed N/A to $3.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 40.0% year-over-year, with the annual reading at $3.0 million for FY2025, 40.0% down from the prior year.
Change in Intangibles for Q3 2025 was $3.0 million at Madrigal Pharmaceuticals, down from $5.0 million in the prior quarter.
The five-year high for Change in Intangibles was $5.0 million in Q2 2024, with the low at $3.0 million in Q3 2025.